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Fatigue is a common symptom in the elderly and has also been associated with impaired 
cognition in older adults. Hence, we sought to explore the cross-sectional relationship 
between fatigue and cerebral β-amyloid (Aβ) in 269 elderly individuals reporting subjective 
memory complaints from the Multidomain Alzheimer Preventive Trial. Standard uptake 
value ratios (SUVRs) were generated by [18F] florbetapir positron emission tomography 
(PET) using the cerebellum as a reference. Cortical-to-cerebellar SUVRs (cortical-SUVRs) 
were obtained using the mean signal from the frontal cortex, temporal cortex, parietal 
cortex, precuneus, anterior cingulate, and posterior cingulate. Other brain regions 
independently assessed were the anterior cingulate, anterior putamen, caudate, hip-
pocampus, medial orbitofrontal cortex, occipital cortex, parietal cortex, pons, posterior 
cingulate, posterior putamen, precuneus, semioval center, and temporal cortex. Fatigue 
was defined according to two questions retrieved from the Center for Epidemiological 
Studies-Depression scale. Chronic fatigue was defined as meeting fatigue criteria at two 
consecutive clinical visits 6 months apart between study baseline and 1 year (visits were 
performed at baseline, 6 months and 1 year then annually). Cross-sectional associations 
between fatigue variables and cerebral Aβ were explored using fully adjusted multiple 
linear regression models. We found no statistically significant cross-sectional associa-
tions between fatigue assessed at the clinical visit closest to PET and Aβ in any brain 
region. Similarly, chronic fatigue was not significantly associated with Aβ load. Sensitivity 
analysis in subjects with a Clinical Dementia Rating of 0.5 showed that fatigue reported 
at the clinical visit closest to PET was, however, weakly associated with increased Aβ in 
the hippocampus (B-coefficient: 0.07, 95% CI: 0.01, 0.12, p = 0.016). These preliminary 
results suggest that fatigue might be associated with Aβ in brain regions associated with 
Alzheimer’s disease in subjects in the early stages of disease.
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inTrODUcTiOn
Fatigue is the sense of persistent general tiredness and exerts a significant negative impact on health 
status (1). It is a common symptom in older adults and has been suggested to serve as a clini-
cally relevant biomarker for pathological aging (2). Fatigue is specifically associated with physical 
frailty (2, 3) and cognitive frailty, where physical frailty presents with cognitive impairments (4, 5). 
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Research into fatigue and Alzheimer’s disease (AD), the most 
common form of dementia in the elderly (6), is limited. However, 
fatigue has been cross-sectionally associated with brain atrophy 
and compromised cognition in cognitively normal older adults 
(7) and longitudinally with increased risk of cognitive decline in 
older adults without dementia (8). Fatigue has also been more 
frequently reported in patients with dementia at 3-year follow-up 
(9) and fatigue is a symptom of depression, a condition that often 
co-presents with dementia (10, 11).
In accordance with the amyloid cascade hypothesis of AD, 
β-amyloid (Aβ) is thought to be the main driver of AD pathol-
ogy culminating in neurofibrillary tangle formation, which in 
turn precipitates neuronal loss and cognitive impairments (12, 
13). It has been suggested that fatigue might occur as a result 
of depleted physiological reserves (14), and fatigue has been 
associated with increased oxidative stress (15). Moreover, 
frailty is associated with pro-inflammatory changes (16–18), 
but due to the biological complexity of the frailty phenotype 
specific associations with its fatigue component are difficult to 
distinguish. It seems plausible, therefore, that fatigue might lead 
to alterations in homeostasis leading to secondary increases 
in Aβ deposition especially considering that oxidative stress 
and inflammation fuel amyloidogenesis (19, 20). Furthermore, 
polypharmacy and conditions prevalent in the elderly such as 
anemia and sleep apnea are associated with fatigue (21–25). 
Sleep apnea has been associated with increased cerebral Aβ (26) 
and iron deficiency leads to alterations in the expression of genes 
involved in amyloidogenesis (27). Moreover, polypharmacy is 
a risk factor for cognitive impairment (28), which potentially 
might manifest through Aβ-dependent mechanisms. Hence, in 
this study, we sought to explore the cross-sectional associations 
between fatigue and cerebral Aβ in older adults reporting subjec-
tive memory complaints. We hypothesized that fatigue would be 
associated with increased cerebral Aβ load.
MaTerials anD MeThODs
The Multidomain alzheimer Preventive 
Trial (MaPT): standard Protocol approvals, 
registrations, and ethics
Data were obtained from a [18F] florbetapir positron emission 
tomography (PET) study carried out as part of the Multidomain 
Alzheimer Preventive Trial (MAPT), which was a large phase III, 
multicentre, randomized, placebo-controlled trial (29) (registra-
tion: NCT00672685). The trial had a four-arm design comprising 
a placebo group and three treatment groups; omega 3 polyun-
saturated fatty acid (n-3 PUFA) supplementation, multidomain 
intervention (involving nutritional and exercise counseling 
and cognitive training), and n-3 PUFA supplementation plus 
multidomain intervention. The trial was designed to assess the 
efficacy of the interventions in slowing cognitive decline in older 
adults at risk of dementia (n = 1,680) (29). In the main analysis 
of MAPT, no significant effects of any of the interventions were 
found on the composite cognitive score compared to placebo after 
adjustment for multiple testing (30). Both the MAPT and [18F] 
florbetapir PET study were approved by the ethics committee in 
Toulouse (CPP SOOM II) and written consent was obtained from 
all participants.
Participants
A total of 271 subjects participated in the MAPT-[18F] florbetapir 
ancillary study. At inclusion, participants were community-
dwelling, men and women without dementia, aged ≥70, and who 
met at least one of the following criteria: spontaneous memory 
complaints, limitation in executing ≥1 Instrumental Activity 
of Daily Living or slow gait speed (<0.8 meters/sec). Two par-
ticipants were excluded because they developed dementia at the 
clinical assessment closest to PET [Clinical Dementia Rating 
(CDR) ≥ 1]. Thus, a total of 269 subjects were included in the 
analyses described here. The participants of the main MAPT 
study not assessed for cerebral Aβ load were similar to the par-
ticipants in the PET sub-study in terms of age at baseline (main 
MAPT study: 75.9 ± 4.5 years, PET sub-study: 75.2 ± 4.2 years), 
sex (main MAPT study: 65.6% female, PET sub-study: 60.2% 
female) and cognition at baseline measured as mini mental state 
examination test score (main MAPT study: 28.0 ± 1.6, PET sub-
study: 28.3 ± 1.5).
[18F] Florbetapir PeT
PET-scans were performed once during MAPT in volunteers 
using [18F] florbetapir as previously described (29, 31). All data 
acquisitions were begun 50  min after injection of a mean of 
4  MBq/kg weight of [18F]-Florbetapir. Radiochemical purity of 
[18F]-Florbetapir was always superior to 99.5%. Standard uptake 
value ratios (SUVRs) were generated from semi-automated 
quantitative analysis using the cerebellum as a reference. 
Cortical-to-cerebellar SUVRs (cortical-SUVRs) were obtained 
using the mean signal from the following cortical regions: frontal, 
temporal, parietal, precuneus, anterior cingulate, and posterior 
cingulate as previously described (32). Other brain regions 
independently assessed were the: anterior cingulate, anterior 
putamen, caudate, hippocampus, medial orbitofrontal cortex, 
occipital cortex, parietal cortex, pons, posterior cingulate, poste-
rior putamen, precuneus, semioval center, and temporal cortex. 
A quality control based on semi-quantification process was also 
performed. The median and interquartile range (IQR) for the 
time interval between baseline and PET-scan assessment was 
487.5 days (IQR: 349–728) and 3.7% (10 out of 269) of subjects 
received a PET-scan at study baseline.
Fatigue
Fatigue was defined according to the following two questions 
retrieved from the Center for Epidemiological Studies-Depression 
scale: (a) I felt that everything I did was an effort, (b) I could not 
get going. The question is asked “How often in the last week did 
you feel this way?” and subjects score their responses: 0 = rarely 
or none of the time (<1 day), 1 =  some or a little of the time 
(1–2 days), 2 = a moderate amount of the time (3–4 days), 3 = most 
of the time. Subjects answering 2 or 3 to either of these questions 
were designated as fatigued otherwise subjects were classed as 
non-fatigued. Subjects were classed as having chronic fatigue if 
answering 2 or 3 to either of the questions at two consecutive 
visits between study baseline and 1 year (visits were performed at 








Age, years 75 (72–79) 76 (73–79) 0.434
Sex, women (%) 134 (59.0%) 28 (66.7%) 0.353
Education (%) 0.190
No diploma or primary school 
certificate
54 (24.1%) 14 (34.1%)
Secondary education no high-
school diploma
72 (32.1%) 7 (17.1%)
High-school diploma 31 (13.8%) 8 (19.5%)
Higher diploma 67 (29.9%) 12 (29.3%)
Group allocation (%) 0.550
Multidomain intervention 57 (28.6%) 11 (26.2%)
n-3 PUFA supplementation 48 (21.1%) 12 (28.6%)
Multidomain intervention and n-3 
PUFA supplementation
65 (28.6%) 8 (19.0%)
Placebo 57 (25.1%) 11 (26.2%)
% of CDR 0.5 (%) 108 (47.6%) 23 (54.7%) 0.392
ApoE ε4 carriers (%)a 53 (26.8%) 12 (32.4%) 0.480
Cortical-SUVR 1.1 (1.0–1.3) 1.1 (1.1–1.3) 0.927
Age and CDR score closest to PET-scan are presented. Data are expressed as median 
(interquartile range) or as absolute values/percentages. Clinical and demographic 
characteristics were compared between the participants deemed as non-fatigued 
or fatigued (with fatigue assessed at the clinical exam closest to PET-scan) using chi 
squared tests for categorical variables and Wilcoxon rank sum tests for continuous 
variables.
ApoE, apolipoprotein E; CDR, clinical dementia rating; n-3 PUFA, omega 3 
polyunsaturated fatty acid; SUVR, standard uptake ratio values.
aApoE ε4 status available for n = 235.
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baseline, 6 months, and 1 year after which they were performed 
annually) otherwise subjects were deemed non-chronically 
fatigued. The adopted definition of fatigue is commonly used to 
define the “exhaustion” criterion in the field of frailty (3).
confounding Variables
On the basis of data availability and the literature on dementia 
(33), we selected the following confounders: age at PET-scan 
assessment, gender, educational level, cognitive status assessed 
at the clinical visit closest to PET-scan (CDR: scores 0 or 0.5), 
MAPT group allocation (four groups: placebo, multidomain 
intervention, n-3 PUFA supplementation and multidomain inter-
vention  +  n-3 PUFA supplementation), depressive symptoms 
assessed closed to PET-scan (Geriatric Depression Scale: scores 
0–30) and Apolipoprotein E ε4 (ApoE ε4) genotype (carriers of 
at least one ε4 allele versus non-carriers).
statistical analysis
Descriptive statistics are presented as median (IQR) or absolute 
values/percentages as appropriate. After completing analysis of 
the primary hypotheses in MAPT (30), we performed post hoc 
analyses using multiple linear regression models to explore the 
cross-sectional relationships between fatigue and cerebral Aβ load 
(measured as SUVR). Clinical and demographic characteristics 
were compared between the participants deemed as non-fatigued 
or fatigued (with fatigue assessed at the clinical exam closest to 
PET-scan) using chi squared tests for categorical variables and 
Wilcoxon rank sum tests for continuous variables. We ran multiple 
linear regression analysis to explore the cross-sectional relation-
ship between fatigue at the clinical exam closest to PET-scan and 
cortical-SUVR and region specific SUVR (13 regions described 
above) adjusting for all confounders. Sensitivity analysis was 
performed in subjects with a CDR score of 0.5 as this sub-group 
represents those more likely to develop AD (34). We also ran 
multiple linear regression analysis to explore the cross-sectional 
relationship between chronic fatigue and cortical-SUVR and 
regional SUVR (13 regions) adjusting for all confounders. There 
was no correction for multiple comparisons due to the explora-
tory nature of this study: p <  0.05 was considered statistically 
significant. All analyses were performed using Stata version 14 
(Stata Corp., College Station, TX, USA).
resUlTs
sample characteristics
Clinical and demographic characteristics of the study partici-
pants are shown in Table 1. The median age of the participants 
was approximately 75 years and around 60% of the subjects were 
female and approximately half of the subjects had a CDR score of 
0.5. Participants exhibited a high educational level and approxi-
mately 30% of the subjects were ApoE ε4 carriers. There were 
no statistically significant differences between subjects classed 
as non-fatigued or fatigued (with fatigue assessed at the clinical 
exam closest to PET-scan). A total of 42 participants out of 269 
(15.6%) were classified as fatigued and of these 42.9% (18 out of 42) 
were Aβ positive using a threshold of mean cortical-SUVR ≥ 1.17 
(31, 35). A total of 26 participants out of 269 (9.7%) were classified 
as having chronic fatigue and of these 38.5% (10 out of 26) were 
Aβ positive.
exploration of the relationship between 
Fatigue and cerebral aβ
There were no statistically significant cross-sectional associations 
of fatigue at the clinical exam closest to PET-scan with cortical 
or region specific Aβ load after adjustment for all confounders 
(Table 2). Sensitivity analysis performed in subjects with a CDR 
score of 0.5, however, showed a weak positive association between 
fatigue reported at the clinical exam closest to PET-scan and Aβ 
load in the hippocampus (Table  3). Chronic fatigue was not 
significantly associated with cortical Aβ or Aβ found in any other 
brain region after adjustment for all confounders (Table 4).
DiscUssiOn
In this study, we did not find any significant cross-sectional 
associations between fatigue (assessed closest to PET-scan 
examination or chronic) and cortical or region specific Aβ load 
in our total study population. However, sensitivity analysis in 
subjects with a CDR of 0.5 showed that fatigue reported closest 
to PET-scan was associated with increased Aβ load specifically in 
the hippocampus.
Why fatigue might be specifically associated with hippocam-
pal Aβ pathology in subjects at increased risk of AD (CDR = 0.5) 
requires further research attention. However, there is evidence 
that fatigue, modeled in rats through the induction of sleep 
TaBle 3 | Multiple linear regressions examining the cross-sectional associations between fatigue at the clinical exam closest to PET-scan and cerebral β-amyloid load in 
subjects with a CDR score of 0.5.
β-amyloid load Unadjusted model (n = 131) adjusted model (n = 113)
B-coeff. 95% ci p-Value B-coeff. 95% ci p-Value
Cortical-SUVR −0.01 −0.09, 0.07 0.829 −0.03 −0.12, 0.05 0.438
SUVR by brain region;
Anterior cingulate 0.01 −0.10, 0.11 0.922 −0.03 −0.15, 0.09 0.597
Anterior putamen −0.01 −0.15, 0.13 0.869 −0.05 −0.21, 0.12 0.585
Caudate 0.08 −0.07, 0.24 0.276 0.11 −0.06, 0.29 0.204
Hippocampus 0.04 −0.01, 0.09 0.106 0.07 0.01, 0.12 0.016
Medial orbitofrontal cortex 0.00 −0.06, 0.06 0.974 0.00 −0.06, 0.06 0.973
Occipital cortex −0.01 −0.10, 0.08 0.750 −0.05 −0.15, 0.04 0.265
Parietal cortex −0.05 −0.14, 0.03 0.241 −0.08 −0.16, 0.01 0.085
Pons 0.01 −0.06, 0.07 0.802 0.01 −0.06, 0.08 0.762
Posterior cingulate −0.01 −0.09, 0.08 0.824 −0.04 −0.13, 0.05 0.426
Posterior putamen −0.01 −0.11, 0.09 0.810 −0.02 −0.14, 0.09 0.693
Precuneus −0.00 −0.12, 0.11 0.958 −0.04 −0.17, 0.08 0.496
Semioval center 0.04 −0.03, 0.12 0.249 0.06 −0.02, 0.15 0.147
Temporal cortex 0.00 −0.07, 0.08 0.904 −0.02 −0.10, 0.06 0.688
The adjusted model contained fewer subjects due to missing data on confounders.
B-coeff, B-coefficient; CI, confidence intervals; p, probability; SUVR, standard uptake ratio values.
TaBle 2 | Multiple linear regressions examining the cross-sectional associations between fatigue at the clinical exam closest to PET-scan and cerebral β-amyloid load.
β-amyloid load Unadjusted model (n = 269) adjusted model (n = 231)
B-coeff. 95% ci p-Value B-coeff. 95% ci p-Value
Cortical-SUVR −0.01 −0.06, 0.05 0.800 −0.04 −0.10, 0.02 0.184
SUVR by brain region;
Anterior cingulate −0.01 −0.08, 0.06 0.832 −0.06 −0.14, 0.02 0.140
Anterior putamen −0.02 −0.12, 0.08 0.683 −0.05 −0.17, 0.06 0.367
Caudate 0.05 −0.06, 0.16 0.344 0.04 −0.09, 0.17 0.532
Hippocampus 0.02 −0.02, 0.06 0.263 0.04 −0.00, 0.08 0.071
Medial orbitofrontal cortex −0.00 −0.05, 0.04 0.939 −0.02 −0.07, 0.03 0.494
Occipital cortex −0.02 −0.08, 0.04 0.553 −0.06 −0.13, 0.01 0.073
Parietal cortex −0.03 −0.09, 0.03 0.339 −0.06 −0.13, 0.01 0.080
Pons −0.01 −0.05, 0.04 0.702 −0.00 −0.06, 0.05 0.896
Posterior cingulate 0.00 −0.06, 0.06 0.975 −0.03 −0.10, 0.04 0.362
Posterior putamen −0.01 −0.09, 0.07 0.727 −0.02 −0.11, 0.07 0.667
Precuneus −0.00 −0.08, 0.08 0.964 −0.05 −0.13, 0.03 0.245
Semioval center 0.02 −0.03, 0.08 0.424 0.02 −0.04, 0.09 0.507
Temporal cortex −0.00 −0.06, 0.05 0.891 −0.03 −0.09, 0.02 0.253
The adjusted model contained fewer subjects due to missing data on confounders.
B-coeff, B-coefficient; CI, confidence intervals; p, probability; SUVR, standard uptake ratio values.
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deprivation, reduces hippocampal as well as cortical dendritic 
spines (36) and inhibits long-term potentiation and hippocampal 
dependent learning tasks (37). Thus, it might be that fatigue also 
modulates cell signaling cascades to promote amyloidogenesis 
specifically in the hippocampus. In line with this, in mouse mod-
els of AD, acute sleep deprivation is associated with increased 
levels of interstitial brain levels of Aβ, whereas chronic sleep 
deprivation has been associated with increased Aβ plaques (38). 
Increased brain Aβ load has also been cross-sectionally associ-
ated with poor sleep (39) and longer sleep latency (time taken to 
fall asleep) (40) in human subjects. Oxidative stress is associated 
with fatigue (15) and pro-inflammatory mediators such as inter-
leukin 6 and C-reactive protein have been associated with frailty 
(which includes fatigue in the phenotype) (16, 18); therefore 
such signalling intermediates might promote fatigue-induced 
amyloidogenesis at the molecular level (19, 20). Interestingly, 
fatigue has also been associated with compromised cognition in 
older adults without dementia (7, 8). With this in mind, fatigue 
might modulate cognition via Aβ-dependent mechanisms in 
human subjects with early AD. More research is needed to verify 
the links between fatigue and Aβ deposition, particularly to rule 
out the possibility that increased Aβ in the brain might precipitate 
fatigue. A better understanding of the biological basis of fatigue 
would facilitate such studies.
The strengths of the current study are the large sample size 
with PET [18F] florbetapir imaging data and the simultaneous 
TaBle 4 | Multiple linear regressions examining the cross-sectional associations between chronic fatigue and cerebral β-amyloid load.
β-amyloid load Unadjusted model (n = 269) adjusted model (n = 231)
B-coeff. 95% ci p-Value B-coeff. 95% ci p-Value
Cortical-SUVR −0.01 −0.08, 0.06 0.854 −0.03 −0.10, 0.05 0.452
SUVR by brain region;
Anterior cingulate −0.01 −0.10, 0.07 0.760 −0.05 −0.14, 0.04 0.293
Anterior putamen 0.02 −0.10, 0.15 0.736 0.01 −0.13, 0.14 0.922
Caudate 0.02 −0.11, 0.16 0.714 0.02 −0.13, 0.17 0.798
Hippocampus −0.01 −0.06, 0.03 0.518 −0.01 −0.06, 0.04 0.677
Medial orbitofrontal cortex −0.01 −0.07, 0.04 0.687 −0.02 −0.08, 0.04 0.433
Occipital cortex −0.01 −0.09, 0.06 0.756 −0.04 −0.12, 0.04 0.286
Parietal cortex 0.00 −0.07, 0.08 0.994 −0.00 −0.08, 0.07 0.903
Pons −0.02 −0.08, 0.03 0.425 −0.02 −0.08, 0.04 0.464
Posterior cingulate −0.01 −0.09, 0.06 0.716 −0.04 −0.12, 0.04 0.384
Posterior putamen −0.00 −0.10, 0.10 0.967 0.01 −0.10, 0.12 0.920
Precuneus 0.01 −0.09, 0.10 0.857 −0.02 −0.12, 0.08 0.639
Semioval center −0.00 −0.07, 0.07 0.943 −0.01 −0.09, 0.07 0.847
Temporal cortex −0.01 −0.07, 0.06 0.773 −0.03 −0.10, 0.04 0.379
The adjusted model contained fewer subjects due to missing data on confounders.
B-coeff, B-coefficient; CI, confidence intervals; p, probability; SUVR, standard uptake ratio values.
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availability of successive fatigue measurements over time enabling 
the creation of a chronic fatigue variable. Nevertheless, there are 
some limitations. The main limitation of this study is that it is 
a secondary analysis of the MAPT imaging sub-study; thus, the 
study was not specifically powered to address our hypothesis 
on the association of fatigue with increased cerebral Aβ load. 
The cross-sectional nature (due to lack of longitudinal imaging 
data) precluded the examination of the relationship between 
fatigue and Aβ temporally. Furthermore, it should be noted that 
PET-scans were performed throughout the three year period 
of MAPT, so the study was not of a true cross-sectional nature. 
Moreover, although used by others (2, 41) as a measure of fatigue, 
the self-reported fatigue variable used here was derived from a 
questionnaire designed to measure depression and as such may 
not robustly capture the physiological component of fatigue but 
rather focus on the psychological element. There was also no data 
available on other diseases that might contribute to fatigue such 
as anemia, sleep apnea, or cancer.
In conclusion, we have shown here that fatigue might be 
associated with increased Aβ in the hippocampus specifically 
in subjects with an augmented risk of AD. Further research is 
required to confirm our preliminary findings. A longitudinal 
study examining the temporal association between fatigue and 
Aβ would provide more evidence as to whether fatigue might 
modulate cerebral Aβ levels.
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